Legal & General Group Portfolio holdings
Legal & General Group Plc, founded in 1836 by six lawyers in London, is a British multinational financial services company headquartered in London, renowned for its leadership in insurance, pensions, and investment management. Managing trillions in assets, the firm operates through key divisions like Legal & General Investment Management (LGIM), one of the UK’s largest asset managers, focusing on index funds, active strategies, and sustainable investing for institutional clients like pension funds. It also provides life insurance, retirement products, and general insurance, serving millions of customers with a strong emphasis on long-term financial security and infrastructure investment, such as affordable housing. With a heritage of stability and a modern push toward ESG (environmental, social, governance) principles, Legal & General remains a cornerstone of the UK financial landscape with a growing global presence.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$657M |
| 2 |
Apple
AAPL
|
+$610M |
| 3 |
Amazon
AMZN
|
+$587M |
| 4 |
AstraZeneca
AZN
|
+$319M |
| 5 |
Snowflake
SNOW
|
+$272M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$323M |
| 2 |
MXIM
Maxim Integrated Products
MXIM
|
+$273M |
| 3 |
WORK
Slack Technologies, Inc.
WORK
|
+$121M |
| 4 |
PFPT
Proofpoint, Inc.
PFPT
|
+$98.6M |
| 5 |
JD.com
JD
|
+$89.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.03% |
| 2 | Financials | 13.72% |
| 3 | Healthcare | 12.6% |
| 4 | Consumer Discretionary | 10.97% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1951
Hamilton Lane
HLNE
$5.57B
| $2.33M | ﹤0.01% |
27,504
+7,293
| +36% | +$653K |
|
1952
LeMaitre Vascular
LMAT
$1.86B
| $2.33M | ﹤0.01% |
43,801
+7,647
| +21% | +$431K |
|
1953
AngioDynamics
ANGO
$649M
| $2.32M | ﹤0.01% |
89,526
+7,967
| +10% | +$213K |
|
|
PENG
1954
Penguin Solutions Inc
PENG
$2.99B
| $2.31M | ﹤0.01% |
104,060
+47,232
| +83% | +$1.13M |
|
|
ARR
1955
Armour Residential REIT
ARR
$2.36B
| $2.29M | ﹤0.01% |
42,571
+6,875
| +19% | +$371K |
|
1956
Lazard
LAZ
$4.31B
| $2.29M | ﹤0.01% |
50,100
-9,781
| -16% | -$456K |
|
1957
LendingTree
TREE
$451M
| $2.29M | ﹤0.01% |
16,376
+2,358
| +17% | +$414K |
|
1958
BJ's Restaurants
BJRI
$1.48B
| $2.29M | ﹤0.01% |
54,718
+4,653
| +9% | +$195K |
|
|
SWCH
1959
DELISTED
Switch, Inc. Class A Common Stock
SWCH
| $2.28M | ﹤0.01% |
89,920
+67,963
| +310% | +$1.59M |
|
1960
Agios Pharmaceuticals
AGIO
$1.93B
| $2.28M | ﹤0.01% |
49,353
+11,069
| +29% | +$535K |
|
1961
DNOW Inc
DNOW
$2.99B
| $2.28M | ﹤0.01% |
297,529
-39,748
| -12% | -$325K |
|
1962
Takeda Pharmaceutical
TAK
$55.7B
| $2.28M | ﹤0.01% |
138,985
| – | – |
|
1963
Gladstone Capital
GLAD
$446M
| $2.28M | ﹤0.01% |
100,526
-6,839
| -6% | -$157K |
|
|
NXGN
1964
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $2.27M | ﹤0.01% |
160,927
+13,221
| +9% | +$206K |
|
1965
Marten Transport
MRTN
$1.22B
| $2.27M | ﹤0.01% |
144,421
+16,707
| +13% | +$262K |
|
1966
BioCryst Pharmaceuticals
BCRX
$2.4B
| $2.26M | ﹤0.01% |
157,547
+111,484
| +242% | +$1.76M |
|
|
LDL
1967
DELISTED
Lydall, Inc.
LDL
| $2.26M | ﹤0.01% |
36,408
+1,456
| +4% | +$89.6K |
|
1968
Andersons Inc
ANDE
$2.22B
| $2.25M | ﹤0.01% |
72,931
-7,433
| -9% | -$214K |
|
|
ITCI
1969
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.25M | ﹤0.01% |
60,295
+13,492
| +29% | +$469K |
|
1970
CryoPort
CYRX
$762M
| $2.24M | ﹤0.01% |
33,702
+24,989
| +287% | +$1.54M |
|
|
RETA
1971
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.24M | ﹤0.01% |
22,253
+5,186
| +30% | +$608K |
|
1972
Designer Brands
DBI
$333M
| $2.24M | ﹤0.01% |
160,514
-30,964
| -16% | -$448K |
|
1973
Vanda Pharmaceuticals
VNDA
$302M
| $2.23M | ﹤0.01% |
130,322
+11,610
| +10% | +$203K |
|
1974
Heartland Express
HTLD
$956M
| $2.23M | ﹤0.01% |
139,363
+6,871
| +5% | +$115K |
|
1975
Schrodinger
SDGR
$1.36B
| $2.23M | ﹤0.01% |
40,776
+10,008
| +33% | +$640K |
|
Similar funds
Legal & General Group's Q3 2021 Portfolio in Review
As of Q3 2021, Legal & General Group held 3,551 positions worth $308B, up 2.9% from $299B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Legal & General Group deployed $10.7B of net new capital in Q3 2021, opening 77 new positions and adding to 2,293 existing holdings. Its largest new stake was AstraZeneca: 2,738,007 shares worth $329M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was JD.com, an estimated $89.3M trimmed.
- Legal & General Group's largest Q3 2021 buy was AstraZeneca: 2,738,007 shares worth $329M.
- Legal & General Group added most to Microsoft in Q3 2021, an estimated $657M increase.
- Legal & General Group's biggest Q3 2021 reduction was JD.com, cutting an estimated $89.3M.
- Legal & General Group fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $323M.
- Legal & General Group's ten largest holdings make up 22% of its $308B portfolio in Q3 2021.
- Legal & General Group opened 77 new positions and closed 55 in Q3 2021.
- Legal & General Group's portfolio value rose 2.9% quarter-over-quarter to $308B.
Based on Legal & General Group's 13F filing for Q3 2021, filed 15 Nov 2021.